Here is a data-driven look at Dr. Reddy's Laboratories Ltd. (DRREDDY), covering financial performance, valuation, and shareholding trends.
Dr Reddy Revenue Trend
For FY2025, Dr. Reddy's Laboratories Ltd. recorded revenue of ₹33,741 Cr. That's 16.7% higher than the ₹28,905 Cr it brought in during FY2024.
The 10-year revenue CAGR of 8.4% reflects steady — if not spectacular — top-line expansion from ₹15,023 Cr to ₹33,741 Cr.
At ₹33,741 Cr in annual revenue, Dr. Reddy's Laboratories Ltd. is one of the major players in the pharmaceuticals space.
Dr. Reddy's Laboratories Ltd. has posted revenue growth for 8 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹33,741 Cr | +16.7% |
| FY2024 | ₹28,905 Cr | +12.4% |
| FY2023 | ₹25,725 Cr | +16.8% |
| FY2022 | ₹22,030 Cr | +15.7% |
| FY2021 | ₹19,048 Cr | — |
View Dr. Reddy's Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Dr Reddy Profitability
The bottom line looked healthy: Dr. Reddy's Laboratories Ltd. posted net profit of ₹5,725 Cr in FY2025, 2.6% above FY2024.
Net margin slipped from 19.3% to 17.0% in FY2025 — a sign of thinning profitability.
On an EPS basis, the company earned ₹67.79 (diluted) in FY2025 versus ₹66.92 in FY2024.
Is Dr Reddy Undervalued
Based on the P/E Ratio model, Dr. Reddy's Laboratories Ltd.'s fair value works out to ₹1,386 — 9.7% upside from where it trades today.
Dr. Reddy's Laboratories Ltd. shares are currently trading at ₹1,263.30.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,386 | 9.7% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Dr. Reddy's Laboratories Ltd. with detailed assumptions →
Dr Reddy Shareholding Pattern
Promoter holding is steady at 26.6% — no buying or selling over the past 4 quarters.
The FII stake is at 33.1% as of March 2026, compared to 36.4% in the year-ago period.
On the domestic institutional side, the holding is 30.7% as of March 2026 — up from 26.7%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 26.6% | 33.1% | 30.7% | 9.3% |
| Dec 2025 | 26.6% | 33.2% | 30.4% | 9.5% |
| Sep 2025 | 26.6% | 35.5% | 28.0% | 9.6% |
| Jun 2025 | 26.6% | 36.4% | 26.7% | 10.0% |
Track quarterly shareholding changes for Dr. Reddy's Laboratories Ltd. →
Dr Reddy Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹494.27B, up 27.2% YoY from ₹388.64B.
Intangibles & Goodwill accounts for 22.2% of the total, ahead of Property, Plant & Equipment (19.6%) and Receivables (18.3%).
Capital structure: 68.6% equity, 9.5% debt, 21.9% operating liabilities. Over the year, debt is up 133.6% and equity is up 20.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 57.91B |
| Receivables | 90.42B |
| Inventories | 71.09B |
| Property, Plant & Equipment | 96.98B |
| Investments | 7.20B |
| Intangibles & Goodwill | 109.94B |
| Other Assets | 60.73B |
| Category | Value |
|---|---|
| Equity | 339.27B |
| Short-term Debt | 38.90B |
| Long-term Debt | 7.86B |
| Trade Payables | 26.48B |
| Other Liabilities | 81.75B |
Dr Reddy Key Takeaways
Here's the bottom line on Dr. Reddy's Laboratories Ltd. (DRREDDY) based on the latest available financials.
Revenue of ₹33,741 Cr in FY2025, up 16.7% year-over-year.
Long-term revenue has been compounding at 8.4% annually over 10 years.
The company is profitable, with a net margin of 17.0% and net income of ₹5,725 Cr.
The P/E Ratio model implies 9.7% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Dr. Reddy's Laboratories Ltd..